Thank you Abdul for your answer. What I really wanted to discuss are the internationally accepted updated indications of these factors in different diseases.
For more information https://www.google.co.in/url?sa=t&source=web&rct=j&url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5184lbl.pdf&ved=0ahUKEwiGyPa_pofUAhUCJ5QKHafPA7YQFggrMAE&usg=AFQjCNErA38mBZ34MRcMCACcAS3oiCxuvg&sig2=Bx-JMW1FGE67a8Wmn8IU5w
1-Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen.
2-Current guidelines recommend their use when the risk of febrile neutropenia is greater than 20%. GM-CSF (sargramostim) is approved for neutropenia associated with stem cell transplantation
3- Current recommendations for the management of patients exposed to lethal doses of total body radiotherapy,